Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525

Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free
free
  English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |   
lüll Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response Yan SF; Ramasamy R; Schmidt AMJ Mol Med (Berl) 2009[Mar]; 87 (3): 235-47The actors in the pathogenesis of diabetes and its complications are many and multifaceted. The effects of elevated levels of glucose are myriad; among these is the generation of advanced glycation end products (AGEs), the products of nonenzymatic glycoxidation of proteins and lipids. The finding that AGEs stimulate signal transduction cascades through the multiligand receptor RAGE unveiled novel insights into diabetes and its complications. Inextricably woven into AGE-RAGE interactions in diabetes is the engagement of the innate and adaptive immune responses. Although glucose may be the triggering stimulus to draw RAGE into diabetes pathology, consequent cellular stress results in release of proinflammatory RAGE ligands S100/calgranulins and HMGB1. We predict that once RAGE is engaged in the diabetic tissue, a vicious cycle of ligand-RAGE perturbation ensues, leading to chronic tissue injury and suppression of repair mechanisms. Targeting RAGE may be a beneficial strategy in diabetes, its complications, and untoward inflammatory responses.|*Signal Transduction[MESH]|Animals[MESH]|Diabetes Mellitus/*metabolism/pathology[MESH]|Glycation End Products, Advanced/*metabolism[MESH]|HMGB1 Protein/metabolism[MESH]|Humans[MESH]|Leukocyte L1 Antigen Complex/metabolism[MESH]|Models, Biological[MESH]|Receptor for Advanced Glycation End Products[MESH]|Receptors, Immunologic/*metabolism[MESH]|S100 Proteins/metabolism[MESH] |